iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone was approved by the FDA on August 13, 2026 to treat Relapsed/refractory multiple myeloma (RRMM).
What did the FDA decide on BMY's iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone?
The FDA decided BMY's (Bristol-Myers Squibb Company) application for iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone on August 13, 2026: Approved. The FDA goal date for this application was 2026-08-17. Verify against the linked primary source.
What is BMY's drug iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone?
iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone is Bristol-Myers Squibb Company's drug, approved by the FDA on August 13, 2026 for Relapsed/refractory multiple myeloma (RRMM).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (763-PDUFA cohort, 2024-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up
Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.